Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-073824
Filing Date
2025-05-16
Accepted
2025-05-16 19:07:25
Documents
1
Period of Report
2025-05-16

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3517
  Complete submission text file 0000950170-25-073824.txt   5016
Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Issuer) CIK: 0001858848 (see all company filings)

EIN.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O TENAYA THERAPEUTICS, INC. 171 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address
Tingley Whittemore (Reporting) CIK: 0001868494 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40656 | Film No.: 25961115